Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants

NCT02745990 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

440

Enrollment

OTHER

Sponsor class

Conditions

Developmental Disabilities

Interventions

DRUG: Recombinant human erythropoietin
DRUG: Normal saline

Sponsor

Huiqing Sun

Collaborators

[object Object]
[object Object]